285 related articles for article (PubMed ID: 11176760)
1. Risedronate: a clinical review.
Crandall C
Arch Intern Med; 2001 Feb; 161(3):353-60. PubMed ID: 11176760
[TBL] [Abstract][Full Text] [Related]
2. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Dunn CJ; Goa KL
Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
[TBL] [Abstract][Full Text] [Related]
3. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Reid DM; Adami S; Devogelaer JP; Chines AA
Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
[TBL] [Abstract][Full Text] [Related]
4. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
5. Risedronate: clinical usage.
Chapurlat RD; Delmas PD
Int J Clin Pract; 2001 May; 55(4):275-8. PubMed ID: 11406915
[TBL] [Abstract][Full Text] [Related]
6. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
7. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
8. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
[TBL] [Abstract][Full Text] [Related]
9. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
Clemmesen B; Ravn P; Zegels B; Taquet AN; Christiansen C; Reginster JY
Osteoporos Int; 1997; 7(5):488-95. PubMed ID: 9425508
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Reginster J; Minne HW; Sorensen OH; Hooper M; Roux C; Brandi ML; Lund B; Ethgen D; Pack S; Roumagnac I; Eastell R
Osteoporos Int; 2000; 11(1):83-91. PubMed ID: 10663363
[TBL] [Abstract][Full Text] [Related]
11. WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Adachi JD; Guyatt G; Papaioannou A; Robinson VA; Shea BJ; Tugwell P; Waldegger LM; Weaver B; Wells G; Zytaruk N
Cochrane Database Syst Rev; 2007 Jul; (1):CD004523. PubMed ID: 17636764
[TBL] [Abstract][Full Text] [Related]
12. Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.
Watts NB
Osteoporos Int; 2001 Dec; 12 Suppl 3():S17-22. PubMed ID: 11846337
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Giljević Z; Vlak T
Reumatizam; 2006; 53(2):66-71. PubMed ID: 17580558
[TBL] [Abstract][Full Text] [Related]
14. Risedronate once a week.
White NJ; Perry CM
Treat Endocrinol; 2003; 2(6):415-20; discussion 421. PubMed ID: 15981945
[TBL] [Abstract][Full Text] [Related]
15. Review of risedronate in the treatment of osteoporosis.
Geusens P; McClung M
Expert Opin Pharmacother; 2001 Dec; 2(12):2011-25. PubMed ID: 11825332
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
[TBL] [Abstract][Full Text] [Related]
17. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Sebba AI; Bonnick SL; Kagan R; Thompson DE; Skalky CS; Chen E; de Papp AE;
Curr Med Res Opin; 2004 Dec; 20(12):2031-41. PubMed ID: 15706659
[TBL] [Abstract][Full Text] [Related]
18. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Fogelman I; Ribot C; Smith R; Ethgen D; Sod E; Reginster JY
J Clin Endocrinol Metab; 2000 May; 85(5):1895-900. PubMed ID: 10843171
[TBL] [Abstract][Full Text] [Related]
19. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.
Cranney A; Tugwell P; Adachi J; Weaver B; Zytaruk N; Papaioannou A; Robinson V; Shea B; Wells G; Guyatt G;
Endocr Rev; 2002 Aug; 23(4):517-23. PubMed ID: 12202466
[TBL] [Abstract][Full Text] [Related]
20. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
